Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part 11 rulemaking planned

This article was originally published in The Gray Sheet

Executive Summary

Updated 1electronic records guidance includes clarification on legacy systems, time stamps and FDA's enforcement discretion policy, as well as an added reference to ISO risk management standard 14971. Accompanied by a 2Sept. 5 Federal Register notice, the August guidance notes that FDA "anticipate[s] initiating rulemaking to change part 11." The decision to alter the electronic records rule stems from the agency's good manufacturing practices initiative for pharmaceuticals. In February, FDA withdrew part 11 guidances and a compliance policy guide and issued an interim draft guidance that announced a number of part 11 requirements would be subject to FDA "enforcement discretion" while FDA reviewed the reg (3"The Gray Sheet" March 3, 2003, p. 7). FDA "currently does not intend to re-issue these draft guidance documents or the CPG," the new guidance notes...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel